Safety Limits Enthusiasm

The headline efficacy is strong, but investors wait for deeper adverse-event, discontinuation, lean-mass, and cardiovascular data before fully underwriting a best-in-class outcome. The market reaction becomes more balanced if gastrointestinal or tolerability issues look meaningful.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.